TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25416480

Group type: EXPERIMENTAL
Intervention: Withdrawal from benzodiazepines (temazepam, zopiclone, zolpidem) over a one-month period.
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Withdrawal from benzodiazepines (temazepam, zopiclone, zolpidem) in women.
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Withdrawal from benzodiazepines (temazepam, zopiclone, zolpidem) in men.
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Withdrawal from benzodiazepines (temazepam, zopiclone, zolpidem).
Number of subjects: 89

Group type: COMPARATOR
Intervention: Non-withwithdrawers (reduced benzodiazepine use).
Number of subjects: 89
Study: 22507886

Group type: EXPERIMENTAL
Intervention: ω‐3 fatty acids (1350 mg of eicosapentaenoic acid and 850 mg of docosahexaenoic acid daily)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 92
Study: 21409920

Group type: EXPERIMENTAL
Intervention: Brand 'A' clopidogrel 600 mg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Brand 'B' clopidogrel 600 mg
Number of subjects: 35
Study: 17961722

Group type: EXPERIMENTAL
Intervention: High-dose therapy followed by autologous transplantation of hematopoietic stem cells (HDT/ASCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal chemoimmunotherapy
Number of subjects: 0
Study: 15505637

Group type: EXPERIMENTAL
Intervention: High-glycemic meal
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low-glycemic meal
Number of subjects: 12
Study: 11950190

Group type: EXPERIMENTAL
Intervention: Oestrogen treatment (oestradiol valerate 2mg once daily)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 9585678

Group type: EXPERIMENTAL
Intervention: Clarithromycin group (amoxicillin 1000 mg twice daily, omeprazole 20 mg twice daily, clarithromycin 250 mg twice daily)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Metronidazole group (amoxicillin 1000 mg twice daily, omeprazole 20 mg twice daily, metronidazole 500 mg twice daily)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 67
Study: 8607304

Group type: EXPERIMENTAL
Intervention: Topical tonsillar spray with 10% lidocaine 4 mg kg‐1 3 minutes before surgical incision
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Topical tonsillar spray with 10% lidocaine after both tonsils had been removed
Number of subjects: 75

Group type: COMPARATOR
Intervention: No topical spray (control group)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Topical lidocaine (both pre- and postoperative)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Pre-operative lidocaine
Number of subjects: 75
Study: 2744908

Group type: EXPERIMENTAL
Intervention: Symmetric dosing with sustained-release theophylline (450 mg b.i.d.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Asymmetric dosing with sustained-release theophylline (270 mg plus 630 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 791605

Group type: EXPERIMENTAL
Intervention: 100 mg propranolol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 5 mg pindolol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31831564

Group type: EXPERIMENTAL
Intervention: Selinexor (60 mg oral) with Gemcitabine (1,000 mg/m2 i.v.) and Nab-Paclitaxel (125 mg/m2 i.v.)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Selinexor-GEM-nab-paclitaxel combination
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Selinexor
Number of subjects: 9
Study: 30755255

Group type: EXPERIMENTAL
Intervention: BI 409306 (10-50 mg daily)
Number of subjects: 457

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 457
Study: 28320312

Group type: EXPERIMENTAL
Intervention: Cognitive aid provided
Number of subjects: 20

Group type: COMPARATOR
Intervention: No cognitive aid
Number of subjects: 20
Study: 23455386

Group type: EXPERIMENTAL
Intervention: Arthroscopy-guided suprascapular nerve block using 10 mL 0.5 % ropivacaine with 1:200,000 epinephrine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo using 10 mL 0.9 % saline
Number of subjects: 30
Study: 23018151

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid with or without clopidogrel
Number of subjects: 4670
Study: 21725239

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control (no pravastatin)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg) and Control
Number of subjects: 152
Study: 19386610

Group type: EXPERIMENTAL
Intervention: Infliximab plus methotrexate (MTX)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo plus methotrexate (MTX)
Number of subjects: 20
Study: 16469019

Group type: EXPERIMENTAL
Intervention: 5 mg CR oxybutynin
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: 10 mg CR oxybutynin
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: 15 mg CR oxybutynin
Number of subjects: 237
Study: 15117983

Group type: EXPERIMENTAL
Intervention: CMF given every 3 weeks for 12 courses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CMF-->DOX (four courses of full-dose DOX followed by eight courses of i.v. CMF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CMF/DOX (alternating two courses of CMF with one course of DOX for a total of 12 courses)
Number of subjects: 0
Study: 11694099

Group type: EXPERIMENTAL
Intervention: In-the-ear (ITE) hearing aid
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Behind-the-ear (BTE) hearing aid
Number of subjects: 29
Study: 9429741

Group type: EXPERIMENTAL
Intervention: Montelukast sodium (MK-0476), 10 mg d-1 for 7 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Montelukast sodium (MK-0476), 7 mg intravenous (5 min infusion)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Montelukast sodium (MK-0476), 10 mg oral dose
Number of subjects: 24
Study: 8381624

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG) 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (NED) 10 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 12
Study: 3690977

Group type: EXPERIMENTAL
Intervention: Inspiratory loading only
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Inspiratory plus expiratory loading
Number of subjects: 18

Group type: COMPARATOR
Intervention: No loading
Number of subjects: 18
Study: 30509399

Group type: EXPERIMENTAL
Intervention: 3G and 4G rapid screening tests or self-tests
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: 4G test
Number of subjects: 512

Group type: COMPARATOR
Intervention: 3G test (sold as a 4G test on a website)
Number of subjects: 512
Study: 27450091

Group type: EXPERIMENTAL
Intervention: Whole-flock treatment with tilmicosin and enhanced biosecurity
Number of subjects: 8146

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 8146
Study: 24462498

Group type: EXPERIMENTAL
Intervention: Technology-supported behavioral intervention
Number of subjects: 122
Study: 22238418

Group type: EXPERIMENTAL
Intervention: PET-positive patients (OEF >1.13)
Number of subjects: 43

Group type: COMPARATOR
Intervention: PET-negative patients (OEF ≤1.13)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: PET-positive patients with TIA as qualifying event
Number of subjects: 43

Group type: COMPARATOR
Intervention: PET-negative patients with TIA as qualifying event
Number of subjects: 43
Study: 21029674

Group type: EXPERIMENTAL
Intervention: Alprostadil injection (10 µg i.v. once every 12 hours for 7 days)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Alprostadil injection
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 63
Study: 18294034

Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided access (group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fluoroscopy-guided access (group 2)
Number of subjects: 100
Study: 15797147

Group type: EXPERIMENTAL
Intervention: Nurse administered intervention
Number of subjects: 294

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 294
Study: 12879464

Group type: EXPERIMENTAL
Intervention: Obese women (BMI >= 30.0 kg/m(2))
Number of subjects: 3759

Group type: EXPERIMENTAL
Intervention: All obese patients
Number of subjects: 3759

Group type: COMPARATOR
Intervention: Normal weight women (BMI 21.0-24.9 kg/m(2))
Number of subjects: 3759

Group type: COMPARATOR
Intervention: Male patients
Number of subjects: 3759
Study: 10489912

Group type: EXPERIMENTAL
Intervention: Pancrelipase capsules
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 8531896

Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg sc)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 1835661

Group type: EXPERIMENTAL
Intervention: Etoposide plus adriamycin plus cisplatin (EAP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etoposide plus 5‐fluorouracil plus leucovorin (ELF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous infusion 5‐fluorouracil plus cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dose methotrexate plus 5‐fluorouracil plus adriamycin (FAMTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5‐fluorouracil, adriamycin and mitomycin (FAM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FAMTX
Number of subjects: 0
Study: 7034916

Group type: EXPERIMENTAL
Intervention: Bumetanide, 2 to 6 mg/d
Number of subjects: 10

Group type: COMPARATOR
Intervention: Furosemide, 40 to 160 mg/d
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 10
Study: 30965355

Group type: EXPERIMENTAL
Intervention: Parent‐sensitivity intervention (PremieStart, n = 60)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Standard care (n = 63)
Number of subjects: 123
Study: 28816687

Group type: EXPERIMENTAL
Intervention: 0.4 mm diameter prosthesis
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 0.6 mm diameter prosthesis
Number of subjects: 18
Study: 24876430

Group type: EXPERIMENTAL
Intervention: Test Meter with in-built insulin calculator
Number of subjects: 164

Group type: COMPARATOR
Intervention: Usual method of testing blood glucose and deciding insulin doses
Number of subjects: 164
Study: 22577270

Group type: EXPERIMENTAL
Intervention: Probiotic complex containing B. bifidum, L. acidophilus, L. casei, and L. salivarius for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (skim milk powder and dextrose)
Number of subjects: 40
Study: 19229814

Group type: EXPERIMENTAL
Intervention: Medical therapy plus renal artery stenting (angioplasty group)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Medical therapy alone (drug therapy group)
Number of subjects: 168
Study: 17312447

Group type: EXPERIMENTAL
Intervention: Xuezhikang
Number of subjects: 591

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 591
Study: 15064916

Group type: EXPERIMENTAL
Intervention: Olanzapine (5-10 mg/day, once or twice daily)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Fluphenazine (5-10 mg/day, once or twice daily)
Number of subjects: 55
Study: 11870677

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg tablet (test formulation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Norvasc 5 mg tablet (reference formulation)
Number of subjects: 24
Study: 9781523

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) monotherapy
Number of subjects: 156

Group type: COMPARATOR
Intervention: Valproic acid (VPA)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 156
Study: 8170179

Group type: EXPERIMENTAL
Intervention: Primary coronary angioplasty without prior thrombolytic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate adjunctive angioplasty after thrombolytic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rescue angioplasty after failed thrombolytic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deferred adjunctive angioplasty during the weeks after infarction
Number of subjects: 0
Study: 3342656

Group type: EXPERIMENTAL
Intervention: MDI with InspirEase (3 puffs of metaproterenol 0.65 mg/puff) plus nebulizer with placebo
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo MDI with InspirEase plus nebulizer with 15 mg metaproterenol
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 75
Study: 2041147

Group type: EXPERIMENTAL
Intervention: 400 mg OFLX (twice daily)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: 600 mg OFLX (twice daily)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: 200 mg OFLX (twice daily)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: 300 mg OFLX (twice daily)
Number of subjects: 113
Study: 1108706

Group type: EXPERIMENTAL
Intervention: Isoflurane (inspired concentration, 1.24%)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Halothane (inspired concentration, 0.77%)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (awake state)
Number of subjects: 12
Study: 30921105

Group type: EXPERIMENTAL
Intervention: Legacy intervention at Los Angeles site
Number of subjects: 541

Group type: COMPARATOR
Intervention: Comparison group at Los Angeles site
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Legacy intervention at Miami site
Number of subjects: 541

Group type: COMPARATOR
Intervention: Comparison group at Miami site
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Legacy intervention at both sites
Number of subjects: 541

Group type: COMPARATOR
Intervention: Comparison group at both sites
Number of subjects: 541
Study: 25989270

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus pimasertib (45 mg/day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus pimasertib (60 mg/day)
Number of subjects: 16
Study: 22621705

Group type: EXPERIMENTAL
Intervention: Yoga group (pranayama and meditation)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (usual rehabilitation care)
Number of subjects: 22
Study: 20979462

Group type: EXPERIMENTAL
Intervention: 1-month cessation
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: 2-month cessation
Number of subjects: 883
Study: 18809689

Group type: EXPERIMENTAL
Intervention: Perceptions of the instructor
Number of subjects: 0
Study: 17306636

Group type: EXPERIMENTAL
Intervention: Laparoscopic 270 degrees Toupet fundoplication
Number of subjects: 56

Group type: COMPARATOR
Intervention: Laparoscopic 360 degrees 'floppy' Nissen fundoplication
Number of subjects: 56
Study: 14985997

Group type: EXPERIMENTAL
Intervention: Maximal walking (WP)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Maximal running (RP)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Isometric knee extension torque
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Isometric knee flexion torque
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Correlation of WP with knee extension torque
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Correlation of WP with knee flexion torque
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Correlation of RP with knee extension torque
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Correlation of RP with knee flexion torque
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Maximal running (RP) adjusted by thigh muscle torque
Number of subjects: 88
Study: 11580742

Group type: EXPERIMENTAL
Intervention: Long-term treatment with six monthly depot injections of leuprolide acetate (LA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Short-term treatment with two monthly LA injections
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intra-operative blood loss
Number of subjects: 36
Study: 9424883

Group type: EXPERIMENTAL
Intervention: Chitosan and lyophilized human placenta dressing
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 50
Study: 7892970

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 72
Study: 3107601

Group type: EXPERIMENTAL
Intervention: Nalbuphine 20 mg i.v.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 20
Study: 29395308

Group type: EXPERIMENTAL
Intervention: Collagen-fibrin patch
Number of subjects: 164

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 164
Study: 29230375

Group type: EXPERIMENTAL
Intervention: Imaging with prior information about normal findings
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Imaging without prior information
Number of subjects: 660

Group type: COMPARATOR
Intervention: Best practice care (quality information without imaging)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Enhanced reporting strategies (for imaging results)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Best practice care
Number of subjects: 660
Study: 25928620

Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV) therapy for 24 weeks along with guideline-directed medical therapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Guideline-directed medical therapy for 24 weeks
Number of subjects: 200
Study: 24066966

Group type: EXPERIMENTAL
Intervention: Triple P Discussion Groups and Stress Control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 0
Study: 22112189

Group type: EXPERIMENTAL
Intervention: PHiD-CV
Number of subjects: 357

Group type: COMPARATOR
Intervention: Control
Number of subjects: 357
Study: 19896571

Group type: EXPERIMENTAL
Intervention: Dexmethylphenidate (D‐MPH)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 16476893

Group type: EXPERIMENTAL
Intervention: Iodine 125 brachytherapy
Number of subjects: 209

Group type: COMPARATOR
Intervention: Enucleation
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Brachytherapy
Number of subjects: 209
Study: 15189800

Group type: EXPERIMENTAL
Intervention: Chronic neuroendocrineimmune dysfunction syndrome (CNDS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chronic fatigue syndrome (CFS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic neuroendocrineimmune dysfunction syndrome, which had formerly been called chronic fatigue syndrome
Number of subjects: 0
Study: 12764804

Group type: EXPERIMENTAL
Intervention: HLA-DRB1 * 0101.2 allele
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: HLA-DRB1 * 0302 allele
Number of subjects: 35

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 35
Study: 8561762

Group type: EXPERIMENTAL
Intervention: Total point prevalence of any specific phobia
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Prevalence of any single specific phobia
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Multiple phobias reported
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Animal phobia prevalence
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Situational phobia prevalence
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Mutilation phobia prevalence
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Fear ratings for all objects and situations
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Inanimate object fears and phobias
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Animal fears intensity
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Fear of flying and fear of injections as a function of age in women
Number of subjects: 704
Study: 2045259

Group type: EXPERIMENTAL
Intervention: Bed rest and hospitalisation for women with viable singleton pregnancies of 7-14 weeks gestation and bleeding in the previous 24 hours.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Emergency scanning as a routine part of the gynaecological service.
Number of subjects: 23

Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned).
Number of subjects: 23
Study: 6337491

Group type: EXPERIMENTAL
Intervention: Cefoxitin (2 gm) at cord clamping
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Three doses of Cefoxitin
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Cefoxitin prophylaxis
Number of subjects: 189
Study: 29278449

Group type: EXPERIMENTAL
Intervention: Enhanced homestead food production programme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measures to overcome water constraints and expand vegetable and poultry production
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retraining of volunteers in food production techniques and nutrition behaviour change counselling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Addition of small incentives for volunteers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collaboration with International Food Policy Research Institute
Number of subjects: 0
Study: 26796500

Group type: EXPERIMENTAL
Intervention: Early Complete Remitters (ECRs) after 4 ECT sessions
Number of subjects: 87

Group type: COMPARATOR
Intervention: Late Complete Remitters (LCRs) after 9 to 12 ECT sessions
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: ECRs
Number of subjects: 87
Study: 25030722

Group type: EXPERIMENTAL
Intervention: Pregabalin and nonsteroidal anti-inflammatory drug combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory drug monotherapy
Number of subjects: 0
Study: 23165739

Group type: EXPERIMENTAL
Intervention: 5‐HT (50 µg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Histamine (0.2 µg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Buffer
Number of subjects: 25
Study: 20801896

Group type: EXPERIMENTAL
Intervention: PROP
Number of subjects: 48

Group type: COMPARATOR
Intervention: NaCl
Number of subjects: 48
Study: 18473097

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 107

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (SXT)
Number of subjects: 107
Study: 15845675

Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg
Number of subjects: 182

Group type: COMPARATOR
Intervention: Propacetamol 2 g
Number of subjects: 182
Study: 12875586

Group type: EXPERIMENTAL
Intervention: Warm water immersion of feet at 42 degrees C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal lidocaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenoxybenzamine (alpha-sympathetic blocking agent) applied to nasal mucosa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetylcholine
Number of subjects: 0
Study: 10442799

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg, n = 184)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Amitriptyline (50-100 mg, n = 191)
Number of subjects: 375